| Edition |
First edition. |
| Description |
1 online resource. |
| Series |
APA practice guidelines |
|
American Psychiatric Association practice guidelines. 1067-8743
|
| Bibliography |
Includes bibliographical references. |
| Note |
Print version record and CIP data provided by publisher; resource not viewed. |
| Contents |
Cover; Title Page; Contents; Acronyms/Abbreviations; Introduction; Overview of the Development Process; Rating the Strength of Research Evidence and Recommendations; Proper Use of Guidelines; Rationale; Guideline Statement Summary; Guideline Statements and Implementation; Assessment and Determination of Treatment Goals; Statement 1: Assessment of Substance Use; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 2: Use of Quantitative Behavioral Measures; Implementation. |
|
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline StatementQuality Measurement Considerations; Statement 3: Use of Physiological Biomarkers; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 4: Assessment of Co-occurring Conditions; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 5: Determination of Initial Treatment Goals; Implementation. |
|
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline StatementQuality Measurement Considerations; Statement 6: Discussion of Legal Obligations; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 7: Review of Risks to Self and Others; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 8: Evidence-Based Treatment Planning; Implementation. |
|
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline StatementQuality Measurement Considerations; Selection of a Pharmacotherapy; Statement 9: Naltrexone or Acamprosate; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 10: Disulfiram; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 11: Topiramate or Gabapentin; Implementation. |
|
Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline StatementQuality Measurement Considerations; Recommendations Against Use of Specific Medications; Statement 12: Antidepressants; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 13: Benzodiazepines; Implementation; Balancing of Potential Benefits and Harms in Rating the Strength of the Guideline Statement; Quality Measurement Considerations; Statement 14: Pharmacotherapy in Pregnant or Breastfeeding Women. |
| Summary |
"Alcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1%, respectively, with approximately half of individuals with lifetime AUD having a severe disorder. AUD and its sequelae also account for significant excess mortality and cost the United States more than $200 billion annually. Despite its high prevalence and numerous negative consequences, AUD remains undertreated. In fact, fewer than 1 in 10 individuals in the United States with a 12-month diagnosis of AUD receive any treatment. Nevertheless, effective and evidence-based interventions are available, and treatment is associated with reductions in the risk of relapse and AUD-associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individuals. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment and treatment planning, which are an integral part of using pharmacotherapy to treat AUD. In addition to reviewing the available evidence on the use of AUD pharmacotherapy, the guideline offers clear, concise, and actionable recommendation statements, each of which is given a rating that reflects the level of confidence that potential benefits of an intervention outweigh potential harms. The guideline provides guidance on implementing these recommendations into clinical practice, with the goal of improving quality of care and treatment outcomes of AUD"--Provided by publisher. |
| Subject |
Alcoholism -- Treatment -- Handbooks, manuals, etc.
|
|
Alcoholism -- Treatment.
(OCoLC)fst00804565
|
|
Alcoholism -- drug therapy.
(DNLM)D000437Q000188
|
|
Alcoholism -- psychology.
(DNLM)D000437Q000523
|
|
HEALTH & FITNESS / Diseases / General
|
|
MEDICAL / Clinical Medicine
|
|
MEDICAL / Diseases
|
|
MEDICAL / Evidence-Based Medicine
|
|
MEDICAL / Internal Medicine
|
| Genre/Form |
Handbooks and manuals. (OCoLC)fst01423877
|
|
Practice Guideline. (DNLM)D017065
|
|
Electronic books.
|
| Added Title |
Practice guideline for the pharmacological treatment of patients with alcohol use disorder |
|
Pharmacological treatment of patients with alcohol use disorder |
| Other Form: |
Print version: American Psychiatric Association, author, issuing body. American Psychiatric Association practice guideline for the pharmacological treatment of patients with alcohol use disorder. First edition. Washington, DC : American Psychiatric Association Publishing, [2018] 9780890426821 (DLC) 2018009605 |
| ISBN |
9780890426838 ) |
|
089042683X |
|
9780890426821 (pb ; alk. paper) |
|
0890426821 |
|
